Similar articles

• Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].

  DeAngelis LM. DeAngelis LM. J Clin Oncol. 2009 Dec 10;27(35):5861-2. doi: 10.1200/JCO.2009.24.5985. Epub 2009 Nov 9. J Clin Oncol. 2009. PMID: 19901101 No abstract available.
• [Chemoradiotherapies for malignant gliomas].

  Aoki T. Aoki T. Nihon Rinsho. 2005 Sep;63 Suppl 9:472-7. Nihon Rinsho. 2005. PMID: 16201566 Review. Japanese. No abstract available.
• [Regulation of MGMT and application for the therapy to attenuate the chemoresistance].

  Kohsaka S, Kanno H, Tanaka S. Kohsaka S, et al. Nihon Rinsho. 2012 Nov;70 Suppl 8:346-52. Nihon Rinsho. 2012. PMID: 23513864 Japanese. No abstract available.
• Temozolomide and MGMT forever?

  Weller M. Weller M. Neuro Oncol. 2010 Mar;12(3):219-20. doi: 10.1093/neuonc/noq016. Neuro Oncol. 2010. PMID: 20167809 Free PMC article. No abstract available.
• Chemotherapy of malignant gliomas.

  Krauseneck P, Müller B. Krauseneck P, et al. Recent Results Cancer Res. 1994;135:135-47. doi: 10.1007/978-3-642-85039-4_14. Recent Results Cancer Res. 1994. PMID: 7519355 Review. No abstract available.